Dr. Pemmaraju on the Ongoing Trial of Tagraxofusp in Myelofibrosis
August 30th 2019Naveen Pemmaraju, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the ongoing phase I/II trial of tagraxofusp (SL-401; Elzonris) in patients with intermediate- or high-risk relapsed/refractory myelofibrosis.
Read More
Dr. Pemmaraju on the Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasms
August 10th 2018Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the trial of SL-401 in blastic plasmacytoid dendritic cell neoplasms.
Read More
Dr. Pemmaraju on SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasms
July 24th 2018Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasms.
Read More
Dr. Pemmaraju on Clinical Trial Results of LCL161 in High-Risk Myelofibrosis
December 13th 2017Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the clinical trial results for LCL161 in patients with intermediate or high-risk myelofibrosis.
Read More
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma
2 Commerce Drive
Cranbury, NJ 08512